The treatment landscape for metastatic castration-resistant prostate cancer has evolved extremely in recent years and several drug classes are now available. Nonetheless, the lack of validated predictive biomarkers makes therapeutic choice and the best sequential approach difficult. The location of the metastatic site could be a valid criterion for choosing among the treatment options available. Although bone remains the most frequent metastatic site and a possible target for many drugs, recent data suggest a profound shift in the disease spectrum with visceral metastases increasing incidence. This review describes the presently available and ongoing therapies for patients with CRPC and bone metastases, focusing on the role of bone metastases as a possible driver for selecting therapies in these patients.
Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice / Roviello, Giandomenico; Catalano, Martina; Ottanelli, Carlotta; Giorgione, Roberta; Rossi, Virginia; Gambale, Elisabetta; Casadei, Chiara; De Giorgi, Ugo; Antonuzzo, Lorenzo. - In: MEDICAL ONCOLOGY. - ISSN 1357-0560. - ELETTRONICO. - 39:(2022), pp. 145.0-145.0. [10.1007/s12032-022-01739-3]
Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice
Roviello, Giandomenico;Catalano, Martina;Ottanelli, Carlotta;Giorgione, Roberta;Rossi, Virginia;Gambale, Elisabetta;Antonuzzo, Lorenzo
2022
Abstract
The treatment landscape for metastatic castration-resistant prostate cancer has evolved extremely in recent years and several drug classes are now available. Nonetheless, the lack of validated predictive biomarkers makes therapeutic choice and the best sequential approach difficult. The location of the metastatic site could be a valid criterion for choosing among the treatment options available. Although bone remains the most frequent metastatic site and a possible target for many drugs, recent data suggest a profound shift in the disease spectrum with visceral metastases increasing incidence. This review describes the presently available and ongoing therapies for patients with CRPC and bone metastases, focusing on the role of bone metastases as a possible driver for selecting therapies in these patients.File | Dimensione | Formato | |
---|---|---|---|
s12032-022-01739-3.pdf
Open Access dal 15/07/2023
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Creative commons
Dimensione
1.23 MB
Formato
Adobe PDF
|
1.23 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.